Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Inhibrx Biosciences Inc ( (INBX) ) is now available.
On May 11, 2026, Inhibrx Biosciences reported positive interim Phase 2 data from its HexAgon trial evaluating INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 high metastatic or unresectable recurrent head and neck squamous cell carcinoma. Of the 53 evaluable patients, the combination arm achieved a 44.0% confirmed objective response rate, including three complete responses, compared with 21.4% and no complete responses in the control arm, with robust T-cell proliferation and a manageable safety profile.
The company plans to advance HexAgon into Phase 3 in the third quarter of 2026 and expects progression-free survival data from the Phase 2 portion in the fourth quarter of 2026, positioning INBRX-106 as a potential first-in-class costimulatory agent that enhances checkpoint inhibitor efficacy. Inhibrx is also preparing to extend INBRX-106 into perioperative and front-line metastatic non-small cell lung cancer and to explore combinations with vaccines, T-cell engagers, and CAR-T therapies, targeting a broad immuno-oncology market opportunity if the early efficacy signals are confirmed.
The most recent analyst rating on (INBX) stock is a Buy with a $230.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.
Spark’s Take on INBX Stock
According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.
The score is held back primarily by weak financial performance driven by persistent losses and heavy cash burn, despite improved leverage. This is partially offset by strong technical momentum and positive pipeline-related corporate updates, while valuation support remains limited due to negative earnings and no dividend information.
To see Spark’s full report on INBX stock, click here.
More about Inhibrx Biosciences Inc
Inhibrx Biosciences Inc. is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates, leveraging proprietary protein engineering platforms and multivalent antibody formats to target complex disease biology. Formed in January 2024 via a spin-out from Inhibrx Inc., its current pipeline includes the OX40 agonist INBRX-106 and ozekibart (INBRX-109), with a strategic focus on immunotherapy-driven oncology indications.
Average Trading Volume: 330,785
Technical Sentiment Signal: Buy
Current Market Cap: $1.96B
For detailed information about INBX stock, go to TipRanks’ Stock Analysis page.